These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16875632)

  • 21. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome.
    Iwaya K; Ogawa H; Izumi M; Kuroda M; Mukai K
    Virchows Arch; 2002 Jun; 440(6):589-93. PubMed ID: 12070597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma.
    Yang W; Klos K; Yang Y; Smith TL; Shi D; Yu D
    Cancer; 2002 Jun; 94(11):2855-61. PubMed ID: 12115372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer.
    Pellikainen J; Kataja V; Ropponen K; Kellokoski J; Pietiläinen T; Böhm J; Eskelinen M; Kosma VM
    Clin Cancer Res; 2002 Nov; 8(11):3487-95. PubMed ID: 12429639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer.
    Giai M; Roagna R; Ponzone R; De Bortoli M; Dati C; Sismondi P
    Anticancer Res; 1994; 14(3B):1441-50. PubMed ID: 7915096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression.
    Roychowdhury DF; Tseng A; Fu KK; Weinburg V; Weidner N
    Cancer; 1996 Apr; 77(8):1419-26. PubMed ID: 8608524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer.
    Kato T; Kameoka S; Kimura T; Nishikawa T; Kobayashi M
    Anticancer Res; 2002; 22(2B):1097-103. PubMed ID: 12168907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer.
    Têtu B; Brisson J; Plante V; Bernard P
    Mod Pathol; 1998 Sep; 11(9):823-30. PubMed ID: 9758361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer.
    Miyake M; Nakano K; Itoi SI; Koh T; Taki T
    Cancer Res; 1996 Mar; 56(6):1244-9. PubMed ID: 8640807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
    el-A Helal T; Khalifa A; Kamel AS
    Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer.
    Sheen-Chen SM; Chou FF; Eng HL; Chen WJ
    Surgery; 1994 Sep; 116(3):510-5. PubMed ID: 8079182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Amplification and overexpression of c-erbB2 in human breast cancer].
    Chen Y; Dong J; Li C
    Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):16-9. PubMed ID: 7656779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vimentin expression does not assist in predicting survival in ductal carcinoma of the breast.
    Heatley MK; Ewings P; Odling Smee W; Maxwell P; Toner PG
    Pathology; 2002 Jun; 34(3):230-2. PubMed ID: 12109782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical significance of c-erbB2 oncoprotein expression in stomach carcinoma].
    Gong Z; Luo E; Lu Q
    Zhonghua Zhong Liu Za Zhi; 1996 Jul; 18(4):299-301. PubMed ID: 9387327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.
    Braun S; Schlimok G; Heumos I; Schaller G; Riethdorf L; Riethmüller G; Pantel K
    Cancer Res; 2001 Mar; 61(5):1890-5. PubMed ID: 11280743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tie-1 tyrosine kinase is an independent prognostic indicator for invasive breast cancer.
    Tseng LM; Hsu CY; Wang HC; Liu JM; Chang HM; Lo SS; Wu CW; Lui WY; Chi CW
    Anticancer Res; 2001; 21(3C):2163-70. PubMed ID: 11501841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relationship between tissue inhibitors of metalloproteinase and metastasis and prognosis in breast cancer].
    Jiang X; Huang X; Li J; Shi Y; Zhou L
    Zhonghua Wai Ke Za Zhi; 2000 Apr; 38(4):291-3, 19. PubMed ID: 12828172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer.
    Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
    Surgery; 2003 Feb; 133(2):219-21. PubMed ID: 12605184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Proliferating cell nuclear antigen (PCNA) in ovarian carcinoma and its relation to lymph node metastasis and prognosis].
    Wu X; Zhang Z; Cai S
    Zhonghua Zhong Liu Za Zhi; 1998 Jan; 20(1):68-70. PubMed ID: 10921065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis.
    Scorilas A; Trangas T; Yotis J; Pateras C; Talieri M
    Br J Cancer; 1999 Dec; 81(8):1385-91. PubMed ID: 10604737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study.
    Hasebe T; Sasaki S; Imoto S; Mukai K; Yokose T; Ochiai A
    Mod Pathol; 2002 May; 15(5):502-16. PubMed ID: 12011255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.